Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19463301 | 1.00 | TSHR (0.47) | TSHRLMNAALDH1A1KAT2BSMN1; SMN2 | |
| SCHEMBL29044559 | 1.00 | TSHR (0.47) | TSHRLMNAALDH1A1KAT2BSMN1; SMN2 | |
| SCHEMBL264567 | 0.98 | TSHR (0.48) | TSHRLMNAALDH1A1KAT2BSMN1; SMN2 | |
| SCHEMBL14141438 | 0.95 | TSHR (0.54) | TSHRLMNAALDH1A1KAT2BSMN1; SMN2 | |
| SCHEMBL2454952 | 0.91 | TSHR (0.50) | TSHRLMNAALDH1A1KAT2BSMN1; SMN2 | |
| SCHEMBL905404 | 0.91 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2HPGDHTTKMT2A | |
| SCHEMBL905700 | 0.91 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2HPGDHTTKMT2A | |
| SCHEMBL379163 | 0.91 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2HPGDHTTKMT2A | |
| SCHEMBL905722 | 0.91 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2HPGDHTTKMT2A | |
| SCHEMBL1870550 | 0.91 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2HPGDHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NOVARTIS AG (CH) | 2023-05-25 | — | — | US | disclosed |
| EP-2264065-B1 | NOVEL INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2017-03-08 | — | — | EP | disclosed |
| US-20140349925-A1 | NOVEL INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2014-11-27 | — | — | US | disclosed |
| US-8828923-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2014-09-09 | — | — | US | disclosed |
| EP-2275439-B1 | Novel insulin derivatives | NOVO NORDISK AS (DK) | 2014-03-26 | — | — | EP | disclosed |
| EP-2107069-B1 | Novel insulin derivatives | NOVO NORDISK AS (DK) | 2013-01-16 | — | — | EP | disclosed |
| EP-2287184-A2 | Novel insulin derivatives | NOVO NORDISK A/S (DK) | 2011-02-23 | — | — | EP | disclosed |
| EP-2275439-A2 | Novel insulin derivatives | NOVO NORDISK A/S (DK) | 2011-01-19 | — | — | EP | disclosed |
| EP-2264065-A2 | Novel Insulin Derivatives | NOVO NORDISK A/S (DK) | 2010-12-22 | — | — | EP | disclosed |
| EP-2264066-A2 | Novel insulin derivatives | NOVO NORDISK A/S (DK) | 2010-12-22 | — | — | EP | disclosed |
| US-20100009899-A1 | Novel Insulin Derivatives | NOVO NORDISK A/S (DK) | 2010-01-14 | — | — | US | disclosed |
| US-7615532-B2 | Antidiabetic agents; insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the alpha-amino group of the N-terminal amino acid residue of the B chain or to epsilon-amino group of a Lys residue present in the B chain of parent insulin | NOVO NORDISK A/S (DE) | 2009-11-10 | — | — | US | disclosed |
| EP-2107069-A2 | Novel insulin derivatives | NOVO NORDISK A/S (DK) | 2009-10-07 | — | — | EP | disclosed |
| US-20060183668-A1 | Antidiabetic agents; insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the alpha-amino group of the N-terminal amino acid residue of the B chain or to epsilon-amino group of a Lys residue present in the B chain of parent insulin | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | US | disclosed |
| EP-1660531-A2 | NOVEL INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005012347-A2 | NOVEL INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NSUN2, NSUN3, POLM | TSHR 2560/4885LMNA 321/4885ALDH1A1 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.